NCT04982055View on ClinicalTrials.gov

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Critical Illness
Interventions
DRUG

Nadroparin (intravenous Infusion)

Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU

DRUG

Nadroparin (subcutaneous group)

Subcutaneous route of administration of nadroparin 3800 IU

All Listed Sponsors
lead

Clinique Saint Pierre Ottignies

OTHER

NCT04982055 - Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients | Biotech Hunter | Biotech Hunter